Physician profile
John K Lee
NPI 1265449722
$24,733.62
in general payments reported to CMS, 2019-2025
45 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $614 · 2021: $1,149 · 2022: $942 · 2023: $1,394 · 2024: $1,441 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $4,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,100.00 |
| Food and Beverage | $4,433.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cytovale, INC. | $17,100.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,024.67 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $988.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $966.54 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $767.40 | 2021-2025 | |
| Amgen INC. | $558.55 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.91 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Glaxosmithkline, LLC. | $340.90 | 2019-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Cranial Technologies, INC | $233.49 | 2019-2025 | Doc Band |
| Currax Pharmaceuticals LLC | $228.54 | 2020-2025 | Contrave, Onzetra Xsail, Nexletol |
| Merck Sharp & Dohme LLC | $220.52 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Pfizer INC. | $218.75 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $143.30 | 2019-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $136.58 | 2022-2024 | Quviviq |
| Abbott Laboratories | $127.05 | 2021-2025 | Freestyle Libre 3 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.